Results 41 to 50 of about 366,991 (303)

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs [PDF]

, 2009
This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging.
Aird, Ang, Barnard, Barnes, Bednarski, Bergamo, Bergamo, Bindoli, Campone, Chatterjee, Che, Chen, Chen, Chen, Chen, Choy, Clarke, Cordier, Desoize, Detty, Dougan, Ernst, Failes, Farrer, Feazell, Fricker, Gabbiani, Gunatilleke, Hall, Hambley, Hamelers, Henderson, Hillard, Hotze, Hotze, Jakupec, Jakupec, Junicke, Kelland, Kostenich, Kostova, Kostrhunova, Li, Mackay, Mackay, Meggers, Mosi, Nguyen, Noor, Oliveira, Ott, Ott, Ott, Peacock, Peacock, Peacock, Peter J. Sadler, Petzold, Petzold, Powis, Rademaker-Lakhai, Sabine H. van Rijt, Sadler, Saggioro, Sergeant, Sessler, Sharman, Shaw, Sherman, Smalley, Storr, Urig, van Rijt, Vessieres, Wang, Wang   +75 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation

Medicina, 2022
Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed.
Hyemi Ko, Myungsun Lee, Eunyoung Cha, Jiyoung Sul, Junbeom Park, Jinsun Lee   +5 more
doaj   +1 more source

Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome [PDF]

, 2012
Background: Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous non-small cell lung cancer.
Aguiar D, Azukizawa H, Barlési F, Bastuji-Garin S, Belani CP, Bosch-Barrera J, Bracke A, Cohen MH, Cornelia Then, Daniel Müller, Del Pozzo-Magana BR, Fuld AD, Grader-Beck T, Harr T, Iung, Jobst C. von Einem, Kardaun SH, Lopes G, Martin Reincke, Michael J. Flaig, Mockenhaupt M, Rudolf M. Huber, Schneck J, Seiwert TY, Shih C, Tan SK, Tummino C, Vitiello M, Yun SJ   +28 more
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source

Activation of the cholinergic anti-inflammatory pathway by GTS-21 attenuates cisplatin-induced acute kidney injury in mice. [PDF]

PLoS ONE, 2017
Acute kidney injury (AKI) is the most common side effect of cisplatin, a widely used chemotherapy drug. Although AKI occurs in up to one third of cancer patients receiving cisplatin, effective renal protective strategies are lacking.
Prodyot K Chatterjee, Michael M Yeboah, Malvika H Solanki, Gopal Kumar, Xiangying Xue, Valentin A Pavlov, Yousef Al-Abed, Christine N Metz   +7 more
doaj   +1 more source

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. [PDF]

, 2015
PurposeTo determine the incidence of chemotherapy-induced nausea/vomiting (CINV) and chemotherapy treatment delay and adherence among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT3 RA) antiemetics.Materials ...
Grabner, Michael, Palli, Swetha Rao, Quimbo, Ralph A, Rugo, Hope S   +3 more
core   +2 more sources